Главная Назад


Авторизация
Идентификатор пользователя / читателя
Пароль (для удалённых пользователей)
 

Вид поиска

Область поиска
в найденном
Найдено в других БД
Формат представления найденных документов:
библиографическое описание краткийполный
Отсортировать найденные документы по:
авторузаглавиюгоду изданиятипу документа
Поисковый запрос: (<.>A=Holst, Jens Juul$<.>)
Общее количество найденных документов : 35
Показаны документы с 1 по 20
 1-20    21-35 
1.
An appetite-suppressing peptide, its compositions and use

2.
An appetite-suppressing peptide, its compositions and use

3.
Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes // Diabetes Care, 2001. Vol. 24, N 4.-С.720-725

4.
Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes // Diabetes Care, 2001. Vol. 24, N 4.-С.720-725

5.
Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men // Diabetes Care, 2001. Vol. 24, N 9.-С.1640-1645

6.
GLP-1 slows solid gastric emptying and inhibits insulin glucagon, and PYY release in humans // Amer. J. Physiol., 1999. Vol. 277, N 3.-С.R910-R916

7.
Short term insulin treatment prevents the diabetogenic actions of streptozotocin in rats // Endocrinology, 1997. Vol. 138, N 1.-С.67

8.
The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects // Clin. Endocrinol., 1998. Vol. 49, N 5.-С.569-572

9.
The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects // Clin. Endocrinol., 1998. Vol. 49, N 5.-С.569-572

10.
Harling Circulating galanin: origin, metabolism, and pharmacokinetics in anesthetized pigs // Amer. J. Physiol., 1992. Vol. 262, N 1.-С.Е52-Е57

11.
The interstinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin // Dig. Diseases and Sci., 2010. Vol. 55, N 10.-С.2785-2796

12.
The interstinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin // Dig. Diseases and Sci., 2010. Vol. 55, N 10.-С.2785-2796

13.
Ostenson Pancreastatin-like immunoreactivity and insulin are released in parallel from the perfused porcine pancreas // Endocrinology, 1989. Vol. 124, N 6.-С.2986-2990

14.
Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual 'бета'-cell function // Diabetes Care, 2011. Vol. 34, N 7.-С.1463-1468

15.
Immunocytochemical demonstration of bombesin immunoreactivity in small cell carcinoma of the lung: A methodological study and review of the literature // Lung Cancer, 1990. Vol. 6, N 1-2.-С.1-8

16.
Glucagon-like peptide-2 increases mesenteric blood flow in humans // Scand. J. Gastroenterol., 2009. Vol. 44, N 3.-С.314-319

17.
Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual 'бета'-cell function // Diabetes Care, 2011. Vol. 34, N 7.-С.1463-1468

18.
Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion // Diabetes, 1998. Vol. 47, N 1.-С.45-49

19.
Glucagon-like peptide 1(7-36) amide stimulates exocytosis in human pancreatic 'бета'-cells by both proximal and distal regulatory steps in stimulus-secretion coupling // Diabetes, 1998. Vol. 47, N 1.-С.57-65

20.
Impaired insulin-stimulated nonoxidative glucose metabolism in pancreas-kidney transplant recipients: Dose-response effects of insulin on glucose turnover // Diabetes, 1996. Vol. 45, N 9.-С.1267-1275

 1-20    21-35 
 




© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)